Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ch Dittrich

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 3, 2004
Targeted therapy--how successful has it been?Ch Dittrich
Wiener Medizinische Wochenschrift (1946)|July 4, 2002
[Pericarditis as the initial manifestation of retroperitoneal fibrosis--a case report]Martina Baur, W Hulla, H Kienzer, et al.
British Journal of Cancer|July 14, 1998
Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cellsGrunt ThW, E Dittrich, M Offterdinger, et al.
British Journal of Cancer|March 10, 2005
Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancerM Baur, E Schernhammer, M Gneist, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administrationCh Dittrich, G Greim, M Borner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validationCh Van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
European Journal of Cancer (Oxford, England : 1990)|September 3, 2004
Targeted therapy--how successful has it been?Ch Dittrich
Wiener Medizinische Wochenschrift (1946)|July 4, 2002
[Pericarditis as the initial manifestation of retroperitoneal fibrosis--a case report]Martina Baur, W Hulla, H Kienzer, et al.
British Journal of Cancer|July 14, 1998
Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cellsGrunt ThW, E Dittrich, M Offterdinger, et al.
British Journal of Cancer|March 10, 2005
Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancerM Baur, E Schernhammer, M Gneist, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administrationCh Dittrich, G Greim, M Borner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validationCh Van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 1